Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2008-12-18
2010-06-15
Kumar, Shailendra (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C554S115000, C554S219000, C554S224000, C562S400000, C562S512000, C562S549000, C562S560000, C514S549000, C514S552000
Reexamination Certificate
active
07737178
ABSTRACT:
Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.
REFERENCES:
patent: 4201211 (1980-05-01), Chandrasekaran et al.
patent: 4442099 (1984-04-01), Nicolau et al.
patent: 4567290 (1986-01-01), Nicolau et al.
patent: 4576758 (1986-03-01), Morris et al.
patent: 4666701 (1987-05-01), Horrobin et al.
patent: 4710521 (1987-12-01), Soukup et al.
patent: 4759880 (1988-07-01), Nicolau et al.
patent: 4810424 (1989-03-01), Gerwick et al.
patent: 5087790 (1992-02-01), Petasis et al.
patent: 5136501 (1992-08-01), Silverman et al.
patent: 5177046 (1993-01-01), Savoca et al.
patent: 5409955 (1995-04-01), Bockow et al.
patent: 5411988 (1995-05-01), Bockow et al.
patent: 5441951 (1995-08-01), Serhan
patent: 5594732 (1997-01-01), Bell et al.
patent: 5604258 (1997-02-01), Ferrante et al.
patent: 5648512 (1997-07-01), Serhan
patent: 5650157 (1997-07-01), Bockow
patent: 5709855 (1998-01-01), Bockow et al.
patent: 5752238 (1998-05-01), Dedrick
patent: 5756789 (1998-05-01), Bruce et al.
patent: 5814599 (1998-09-01), Mitragotri et al.
patent: 5842040 (1998-11-01), Hughes et al.
patent: 5845265 (1998-12-01), Woolston
patent: 5846974 (1998-12-01), Kallman et al.
patent: 5861399 (1999-01-01), Seed et al.
patent: 5870717 (1999-02-01), Wiecha
patent: 5878400 (1999-03-01), Carter, III
patent: 5878423 (1999-03-01), Anderson et al.
patent: 5890138 (1999-03-01), Godin et al.
patent: 5896379 (1999-04-01), Haber
patent: 5912006 (1999-06-01), Bockow et al.
patent: 5932598 (1999-08-01), Talley et al.
patent: 5946467 (1999-08-01), Pathakis et al.
patent: 6030715 (2000-02-01), Thompson et al.
patent: 6030917 (2000-02-01), Weinberg et al.
patent: 6048897 (2000-04-01), Serhan
patent: 6069109 (2000-05-01), Kao et al.
patent: 6117911 (2000-09-01), Grainger et al.
patent: 6201022 (2001-03-01), Mease et al.
patent: 6232467 (2001-05-01), Petasis et al.
patent: 6259699 (2001-07-01), Opalka et al.
patent: 6272474 (2001-08-01), Garcia
patent: 6316648 (2001-11-01), Serhan
patent: 6336105 (2002-01-01), Conklin et al.
patent: 6336138 (2002-01-01), Caswell et al.
patent: 6377937 (2002-04-01), Paskowitz
patent: 6397212 (2002-05-01), Biffar
patent: 6415270 (2002-07-01), Rackson et al.
patent: 6427132 (2002-07-01), Bowman-Amuah
patent: 6428990 (2002-08-01), Mukerji et al.
patent: 6569075 (2003-05-01), Serhan
patent: 6602817 (2003-08-01), Petasis
patent: 6620919 (2003-09-01), Serhan
patent: 6635776 (2003-10-01), Serhan
patent: 6653493 (2003-11-01), Serhan
patent: 6670396 (2003-12-01), Serhan et al.
patent: 6750360 (2004-06-01), Serhan
patent: 6887901 (2005-05-01), Serhan
patent: 6949664 (2005-09-01), Petasis
patent: 7030159 (2006-04-01), Serhan et al.
patent: 7053230 (2006-05-01), Serhan et al.
patent: 7341840 (2008-03-01), Serhan et al.
patent: 2001/0023500 (2001-09-01), Serhan
patent: 2001/0031882 (2001-10-01), Serhan
patent: 2002/0010351 (2002-01-01), Serhan
patent: 2002/0045579 (2002-04-01), Madara et al.
patent: 2002/0055538 (2002-05-01), Serhan et al.
patent: 2002/0055539 (2002-05-01), Bockow et al.
patent: 2002/0082435 (2002-06-01), Serhan
patent: 2002/0091279 (2002-07-01), Serhan
patent: 2002/0094549 (2002-07-01), Serhan et al.
patent: 2002/0107289 (2002-08-01), Serhan
patent: 2002/0111505 (2002-08-01), Serhan
patent: 2002/0120013 (2002-08-01), Serhan
patent: 2002/0132847 (2002-09-01), Serhan
patent: 2002/0143069 (2002-10-01), Serhan
patent: 2002/0193431 (2002-12-01), Serhan et al.
patent: 2003/0032827 (2003-02-01), Serhan
patent: 2003/0055275 (2003-03-01), Serhan
patent: 2003/0060512 (2003-03-01), Madara et al.
patent: 2003/0069435 (2003-04-01), Serhan
patent: 2003/0134901 (2003-07-01), Serhan
patent: 2003/0166716 (2003-09-01), Serhan et al.
patent: 2003/0191184 (2003-10-01), Serhan et al.
patent: 2003/0191332 (2003-10-01), Serhan
patent: 2003/0195248 (2003-10-01), Serhan et al.
patent: 2003/0236423 (2003-12-01), Petasis
patent: 2004/0019110 (2004-01-01), Van Dyke et al.
patent: 2004/0044028 (2004-03-01), Obukowicz
patent: 2004/0044050 (2004-03-01), Goodman et al.
patent: 2004/0053998 (2004-03-01), Serhan et al.
patent: 2004/0059144 (2004-03-01), Serhan et al.
patent: 2004/0116408 (2004-06-01), Serhan
patent: 2004/0151712 (2004-08-01), Madara et al.
patent: 2004/0192785 (2004-09-01), Serhan
patent: 2005/0075398 (2005-04-01), Bazan et al.
patent: 2005/0228047 (2005-10-01), Petasis
patent: 2005/0261255 (2005-11-01), Serhan et al.
patent: 2006/0128804 (2006-06-01), Serhan et al.
patent: 2006/0293288 (2006-12-01), Serhan et al.
patent: 2008/0096961 (2008-04-01), Serhan et al.
patent: 0736509 (1996-10-01), None
patent: 2033745 (1980-05-01), None
patent: 5186342 (1993-07-01), None
patent: WO 91/16914 (1991-11-01), None
patent: WO 97/19415 (1997-05-01), None
patent: WO 98/19259 (1998-05-01), None
patent: WO 98/35469 (1998-08-01), None
patent: WO 98/46588 (1998-10-01), None
patent: WO 99/06913 (1999-02-01), None
patent: WO 99/13417 (1999-03-01), None
patent: WO 99/56727 (1999-11-01), None
patent: WO 00/32210 (2000-06-01), None
patent: WO 00/74632 (2000-12-01), None
patent: WO 01/60778 (2001-08-01), None
patent: WO 03/051350 (2003-06-01), None
patent: WO 03/053123 (2003-07-01), None
patent: WO 03/053423 (2003-07-01), None
patent: WO 03/084305 (2003-10-01), None
patent: WO 03/105776 (2003-12-01), None
patent: WO 2004/014835 (2004-02-01), None
patent: WO 2005/089744 (2005-09-01), None
“Scope and Editorial Policy”,Organometallics, published by the American Chemical Society 21 (1) 2002, 13A, 14A.
“Epolinsatures”, Bulletin De La Societe Chimique de France, No. 3, pp. 419-432, 1989.
XP002184773. Database WPI, Section Ch, Week 199334. Derwent Publications Ltd., London, GB; AN 1993-269748. (See also JP 05186342, Jul. 27, 1993).
Alami, et al., A Versatile Route to conjugated hydroxyl (e,z,e,e)—Tetraenoic acids: highly chemo-and stereoselective synthesis of lipoxin B4 Tetrahedro Asym., 8 (17) 1997, pp. 2949-2958.
Albert, C. M. et al., “Blood levels of long-chain n-e fatty acids and the risk of sudden death”,N. Engl. J. Med., vol. 346, 2002, pp. 1113-1118.
Arita et al., “Stereochemical Assignment, Antiinflammatory Properties, and Receptor for the Omega-3 Lipid Mediator Resolvin E1”,J. Exp. Med. 201(5) 2005, 713-722.
Arita, et al., “Resolvin E1, An Endogenous Lipid Mediator Derived from Omega-3 Eicosapentaenoic Acid, Protects Against 2, 4,6-Trinitrobenzene Sulfonic Acid-induced Colitis”,Proc. Natl. Acad. Sci, USA, 102(21) 2005, pp. 7671-7676.
Babine, R.E. and S.L. Bender., “Molecular Recognition of Protein-Ligand Complexes: Applications to Design”,Chem. Rev, 97, 1997, pp. 1359-1472.
Bandeira-Mielo et al., “Cyclooxygenase-2 derived prostaglandin E2and lipoxin A4accelerate resolution of allergic edema in Antiostrongylus costaricensis-infected rats: relationship with concurrent eosinophilia”,J. Immunol., vol. 164, 2000, pp. 1029-1036.
Bannenberg, et al., “Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins”,Immunol. 174(7) 2005, pp. 4345-4355.
Bazan, et al., “Docosahexaneoic Acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina”,Biochem. Biophys. Res. Comm., vol. 125, 1984, pp. 741-747.
Bazan et al., “Pathways for the uptake and conservation of docosahexaenoic acid in photoreceptors and synapses: biochemical and autoradiographic studies”,Can. J. Physiol. Pharmacol., vol. 71, 1993, pp. 690-698.
Beamer L.J. et al. “Crystal structure of Human BPI and two bound phospholipids at 2.4 angstrom resolution”,Science, vol. 276, 1997, pp. 1861-1864.
Bhaley, G. et al., “Solid Phase Synthesis of Diverse Tetrahydro-1,4- Benzodiazepine-2-ones”,Tetrahedron Letters38(48) 1997, pp. 8375-8378.
Biliman et al., “Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs”,Circulation 99,1999, pp. 2452-2457.
Blaser, E. et al., “Asymmetrix Steering of oxa Diels-Aid
Clish Clary B.
Serhan Charles N.
Fairman Colin L.
Fulbright & Jaworski LLP
Kumar Shailendra
Rothenberger Scott D.
The Brigham and Woman's Hospital, Inc.
LandOfFree
Aspirin-triggered lipid mediators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aspirin-triggered lipid mediators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aspirin-triggered lipid mediators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244451